Overview
On November 14 the National Healthcare Security Administration and the Ministry of Human Resources and Social Security released the 2026 National Basic Medical Insurance, Maternity Insurance and Work Injury Insurance Drug Catalogue together with the Commercial Health Insurance Innovative Drug Catalogue, completing the ninth routine catalogue revision since the administration was founded. The new basic catalogue adds 107 drugs, 51 of them Class 1 innovative medicines - a record high - covering oncology, rare diseases, chronic conditions and psychiatric disorders. It removes 34 drugs with limited clinical value, better alternatives, or incomplete labelling and unavailable supply. After additions, removals and dosage-form consolidation, the net increase is 78 entries, bringing the total to 3,331 drugs: 1,935 Western medicines and 1,396 traditional Chinese patent medicines, with 885 herbal decoction pieces after renumbering under the 2025 Pharmacopoeia. The new catalogues take effect on January 1, 2027.
The commercial innovative drug catalogue was revised in parallel, adding 12 medicines including the world’s first CAR-T therapy for solid tumours and China’s first gene therapy for haemophilia, bringing the list to 28. The more consequential change is institutional: a linkage mechanism between the commercial list and the basic catalogue was established for the first time, and two products from the 2025 commercial list entered the new basic catalogue. The administration’s medical services department reports that by the end of October, the 19 drugs on the 2025 commercial list had been stocked by 1,710 medical institutions and designated retail pharmacies, serving nearly 30,000 patient episodes and generating about 600 million yuan in drug sales. The number of stocking institutions rose roughly 140% and monthly sales 70% versus pre-listing levels.
The notice also addresses implementation: commercial insurers are supported in designing new products, updating coverage scopes and adjusting claims methods based on the revised list; qualified regions are encouraged to pilot one-stop settlement across basic medical insurance, work injury insurance and commercial health insurance; and local authorities are asked to arrange institutional stocking, clinician training and policy communication.
Background & Interpretation
1. Regulatory and Industry Context
Multi-tier health coverage has long faced a structural problem: newly launched high-cost innovative drugs carry limited clinical data, and a basic fund mandated to cover essentials cannot absorb them immediately, leaving patients with heavy out-of-pocket costs and manufacturers without a volume channel. The commercial innovative drug list lets commercial health insurance take that demand first, with no basic-fund payment; once efficacy, cost and affordability are better established, the linkage mechanism allows transfer into the basic catalogue. Two products completing that commercial-first, basic-insurance-second transition this year means the pathway has moved from design to a working closed loop.
2. Core Drivers and Underlying Mechanism
The revision follows value-based purchasing: pharmacoeconomic evaluation and fund-impact modelling feed a comprehensive assessment, and negotiation or competitive bidding sets the payment standard, balancing patient burden against fund sustainability. Entry of CAR-T therapies priced above one million yuan and non-factor haemophilia treatments reflects both negotiated price reductions and lower costs from domestic production of key raw materials. For insurers, the list supplies an expert-reviewed, price-negotiated set of medicines, cutting the information cost of validating high-cost drugs and defining coverage terms.
3. Market Structure and Industry Chain Impact
Competition in health insurance shifts from sum insured and premium toward drug lists, coverage scope and settlement experience. Carriers that quickly bring the 28 listed drugs into coverage and connect to one-stop settlement gain differentiation in the mid-to-high-end segment; those whose policy wording lags the catalogue risk claims disputes. For pharmaceutical firms, the commercial list opens a pre-reimbursement commercialisation window - the roughly 140% rise in stocking institutions and 70% rise in monthly sales quantify its value. Hospitals and pharmacies face higher requirements for procurement, cold chain and pharmaceutical care around high-cost therapies.
Implications & Outlook
Near term, watch implementation before the January 1, 2027 start date: provincial supporting rules, institutional stocking progress, the pace of policy-wording updates, and whether one-stop settlement pilots replicate beyond initial sites. Medium term, three variables matter: actual claims ratios and patient episodes for listed drugs, how many products the linkage mechanism transfers each year, and the effect of high-cost therapies on the basic fund’s expenditure mix. Over time, if commercial-first, basic-second becomes routine, innovative drug payment will evolve from a single negotiation into staged, layered funding, and health insurance’s role will shift from cost reimbursement toward access and payment management.
Takeaways for Industry Participants
Insurers should build wording-update processes synchronised with catalogue revisions, specifying coverage scope, deductibles and pre-existing-condition treatment for newly listed drugs, and connect settlement interfaces with providers ahead of time so claims definitions do not lag implementation. Pricing should rest on real patient-episode and claims data rather than a mechanical rate cut as the list expands; for ultra-high-cost CAR-T and gene therapies, benefits tied to indications and confirmed efficacy are worth exploring. Pharmaceutical companies can fold the commercial window into launch planning and use real-world utilisation data to support later basic-fund negotiation. Providers should strengthen procurement, storage and adverse-event monitoring for high-value medicines in parallel.
This column compiles industry information and shares technical perspectives; it does not constitute investment advice.